BTIG Reaffirms Buy Recommendation for NRx Pharmaceuticals, Sees 1,540.09% Upside

BTIG reiterated its Buy recommendation for NRx Pharmaceuticals (NasdaqCM:NRXP) with a price target of $37.23/share, a 1,540.09% increase from its latest closing price of $2.27/share. The projected annual revenue for NRx Pharmaceuticals is 0MM, a decrease of 100.00%, and the projected annual non-GAAP EPS is -0.36. 36 funds or institutions are reporting positions in NRx Pharmaceuticals, with an average portfolio weight of 0.25%.